アルデシンＡＱネーザルの鼻閉に対する効果　　小児アレルギー性鼻炎例での検討

DOI Web Site 参考文献28件

書誌事項

タイトル別名
  • Effect of Beclomethasone Dipropionate Aqueous Nasal Spray on Nasal Obstruction in Pediatric Patients with Perennial Nasal Allergy.
  • アルデシンAQ ネーザル ノ ビヘイ ニ タイスル コウカ ショウニ ア
  • ―小児アレルギー性鼻炎例での検討―

この論文をさがす

抄録

The author evaluated the efficacy of beclomethasone dipropionate aqueous nasal spray (BDANS) at 300μg/day for 2 weeks, followed by 100μg/day for 1-8 weeks, on nasal obstruction in 12 pediatric patients (9 males and 3 females, aged 6-14 years, mean age 8.8 years) with perennial nasal allergy symptoms. A 100mm visual analogue scale (VAS) was used for subjective measurement of the nasal sensation of airflow, and acoustic rhinometry (AR) was used for objective measurement of the nasal cavity dimensions on entering the trial, and at 1, 2 and 3-11 weeks after the start of medication.<br>1. The mean±standard error (SE) of the VAS score was 45.8±8.3 before treatment, 14.3±4.0 at one week, 14.0±2.8 at two weeks, and 22.9±4.3 at more than 3 weeks after the start of medication. The Friedman test for overall analysis showed significant variance in the VAS scores (P=0.0070).<br>2. The mean±SE of the right+left minimum cross-sectional area of the nose (MCA) was 0.29±0.06cm2 before treatment, 0.46±0.04cm2 at one week, 0.45±0.04cm2 at two weeks, and 0.44±0.05cm2 at more than 3 weeks after the start of medication. The Friedman test showed significant variance in the MCA values (P=0.0045).<br>3. The mean±SE of the right+left nasal cavity volume (NCV) was 4.50±0.46cm3 before treatment, 5.66±0.40cm3 at one week, 5.69±0.39cm3 at two weeks, and 5.39±0.34cm3 at more than 3 weeks after the start of medication. The Friedman test showed significant variance in the NCV values (P=0.0002).<br>In conclusion, the present VAS and AR studies demonstrated that BDANS was effective in reducing allergy-induced nasal obstruction in children.

収録刊行物

参考文献 (28)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ